Nagai Y - Search Results

1

A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77.

Chen X, Nagai Y, Zhu Z, Ruan H, Peehl DM, Greene MI, Zhang H. Chen X, et al. Among authors: nagai y. Oncotarget. 2017 Dec 16;9(3):3631-3640. doi: 10.18632/oncotarget.23341. eCollection 2018 Jan 9. Oncotarget. 2017. PMID: 29423071 Free PMC article.

2

A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ.

Zhang H, Lam L, Nagai Y, Zhu Z, Chen X, Ji MQ, Greene MI. Zhang H, et al. Among authors: nagai y. Oncoimmunology. 2018 Feb 8;7(4):e1300739. doi: 10.1080/2162402X.2017.1300739. eCollection 2018. Oncoimmunology. 2018. PMID: 29632709 Free PMC article.

3

PRMT5 Is Required for T Cell Survival and Proliferation by Maintaining Cytokine Signaling.

Tanaka Y, Nagai Y, Okumura M, Greene MI, Kambayashi T. Tanaka Y, et al. Among authors: nagai y. Front Immunol. 2020 Apr 9;11:621. doi: 10.3389/fimmu.2020.00621. eCollection 2020. Front Immunol. 2020. PMID: 32328070 Free PMC article.

4

Molecular and biological role of the FOXP3 N-terminal domain in immune regulation by T regulatory/suppressor cells.

Deng G, Xiao Y, Zhou Z, Nagai Y, Zhang H, Li B, Greene MI. Deng G, et al. Among authors: nagai y. Exp Mol Pathol. 2012 Dec;93(3):334-8. doi: 10.1016/j.yexmp.2012.09.013. Epub 2012 Oct 2. Exp Mol Pathol. 2012. PMID: 23041265 Free PMC article. Review.

5

scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors.

Cai Z, Fu T, Nagai Y, Lam L, Yee M, Zhu Z, Zhang H. Cai Z, et al. Among authors: nagai y. Cancer Res. 2013 Apr 15;73(8):2619-27. doi: 10.1158/0008-5472.CAN-12-3920. Epub 2013 Feb 8. Cancer Res. 2013. PMID: 23396586 Free PMC article.

6

Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers.

Du T, Nagai Y, Xiao Y, Greene MI, Zhang H. Du T, et al. Among authors: nagai y. Exp Mol Pathol. 2013 Aug;95(1):38-45. doi: 10.1016/j.yexmp.2013.04.003. Epub 2013 May 2. Exp Mol Pathol. 2013. PMID: 23644046 Free PMC article.

7

Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors.

Nagai Y, Tsuchiya H, Runkle EA, Young PD, Ji MQ, Norton L, Drebin JA, Zhang H, Greene MI. Nagai Y, et al. Cell Rep. 2015 Sep 29;12(12):2049-59. doi: 10.1016/j.celrep.2015.08.044. Epub 2015 Sep 10. Cell Rep. 2015. PMID: 26365188 Free PMC article.

8

PRMT5 Associates With the FOXP3 Homomer and When Disabled Enhances Targeted p185^erbB2/neu Tumor Immunotherapy.

Nagai Y, Ji MQ, Zhu F, Xiao Y, Tanaka Y, Kambayashi T, Fujimoto S, Goldberg MM, Zhang H, Li B, Ohtani T, Greene MI. Nagai Y, et al. Front Immunol. 2019 Feb 8;10:174. doi: 10.3389/fimmu.2019.00174. eCollection 2019. Front Immunol. 2019. PMID: 30800128 Free PMC article.

9

Dynamic interactions between TIP60 and p300 regulate FOXP3 function through a structural switch defined by a single lysine on TIP60.

Xiao Y, Nagai Y, Deng G, Ohtani T, Zhu Z, Zhou Z, Zhang H, Ji MQ, Lough JW, Samanta A, Hancock WW, Greene MI. Xiao Y, et al. Among authors: nagai y. Cell Rep. 2014 Jun 12;7(5):1471-1480. doi: 10.1016/j.celrep.2014.04.021. Epub 2014 May 15. Cell Rep. 2014. PMID: 24835996 Free PMC article.

10

Foxp3 Post-translational Modifications and Treg Suppressive Activity.

Deng G, Song X, Fujimoto S, Piccirillo CA, Nagai Y, Greene MI. Deng G, et al. Among authors: nagai y. Front Immunol. 2019 Oct 18;10:2486. doi: 10.3389/fimmu.2019.02486. eCollection 2019. Front Immunol. 2019. PMID: 31681337 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,985 results

Search Page

Filters